By Frank Prenesti
Date: Friday 19 Mar 2021
LONDON (ShareCast) - (Sharecast News) - Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.
Sanofi had given notice to "terminate the collaboration and license agreement for process development and manufacturing of lentiviral vectors to treat haemophilia", Oxford said on Friday.
"The group expects that the impact on revenue will be negligible over the coming 24 month period."
Email this article to a friend
or share it with one of these popular networks:
Currency | Euro |
Share Price | 97.11 |
Change Today | -1.60 |
% Change | -1.62 % |
52 Week High | 105.76 |
52 Week Low | 83.65 |
Volume | 2,710,235 |
Shares Issued | 13.45m |
Market Cap | 1,306.13m |
Beta | 0.45 |
Strong Buy | 12 |
Buy | 8 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 1 |
Total | 26 |
Time | Volume / Share Price |
17:35 | 335 @ 97.11 |
17:35 | 100 @ 97.11 |
17:35 | 100 @ 97.11 |
17:35 | 100 @ 97.11 |
17:35 | 100 @ 97.11 |
You are here: research